Following a limited submission
AWMSG advice |
|
| Status: Recommended | |
Guanfacine (Intuniv®) PR is recommended for use within NHS Wales for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Guanfacine (Intuniv®) PR must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures. |
|
Medicine details |
|
| Medicine name | guanfacine (Intuniv®) |
| Formulation | 1 mg, 2 mg, 3 mg and 4 mg prolonged-release tablets |
| Reference number | 6440 |
| Indication | Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Guanfacine must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures |
| Company | Takeda UK Limited |
| BNF chapter | Central nervous system |
| Assessment type | Limited |
| Status | Recommended |
| Scrutiny Panel meeting date | 09/01/2025 |
| LOWMAG meeting date | 07/04/2025 |
| AWMSG meeting date | 20/05/2025 |
| Date of issue | 29/05/2025 |
| Further information This advice replaces the AWMSG recommendation previously issued in June 2016 (AWTTC reference number 2361). |
|